Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

{
  "signal_id": "0b92fb05-18cc-5c85-2bc2-9c089c9ccc97",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-07-29T10:59:00+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-gwyn-lo-a-once-weekly-contraceptive-patch-302837674.html",
    "title": "Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch",
    "excerpt": "New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option Approval Marks an Important Milestone in Viatris' Efforts to Advance Women's Health PITTSBURGH , July 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS ), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbearing potential with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for CHC. The Gwyn Lo dosage is norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day. \"Gwyn Lo will provide a discreet option for women seeking a reversible, non-invasive, once-weekly contraception patch with a low dose of estrogen,\" said Philippe Martin , Viatris Chief R&D Officer. \"Building on our expertise in transdermal drug delivery systems and legacy in women's health, we are pleased that the approved label for this new patch reflects the strength of our clinical program. This includes demonstrated efficacy in women with a BMI of 25 to less than 30 kg/m², with no BMI-based limitation of use in this population.\" The approval was granted under the FDA's 505(b)(2) regulatory pathway and was supported by results from the...",
    "product": "Gwyn Lo",
    "summary": "Viatris received U.S. FDA approval for Gwyn Lo, a new once-weekly combined hormonal contraceptive patch with low-dose estrogen.",
    "location": "Pittsburgh, Pennsylvania, USA",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS627787/Viatris-OUS-Logo.jpg?id=OA2798849&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "Gwyn Lo",
      "full_text": "Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-07-29T10:59:00Z",
    "location_data": [
      {
        "city": "Pittsburgh",
        "state": "Pennsylvania",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-07-29",
    "article_sentence": "Viatris Inc. (Nasdaq: VTRS ), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system)."
  }
}

curl https://signals.autobound.ai/v1/signals/0b92fb05-18cc-5c85-2bc2-9c089c9ccc97 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"viatris.com","limit":20}'